IRIS
BUTTITTA, Fiamma
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.252
EU - Europa 3.248
AS - Asia 2.999
SA - Sud America 412
AF - Africa 33
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 7
Totale 10.959
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.156
SG - Singapore 1.269
CN - Cina 950
UA - Ucraina 540
IE - Irlanda 481
IT - Italia 474
GB - Regno Unito 438
SE - Svezia 399
BR - Brasile 343
TR - Turchia 321
FR - Francia 299
DE - Germania 244
IN - India 141
VN - Vietnam 125
FI - Finlandia 117
RU - Federazione Russa 98
CA - Canada 54
PL - Polonia 36
AR - Argentina 31
MX - Messico 31
KR - Corea 27
HK - Hong Kong 23
JP - Giappone 23
CZ - Repubblica Ceca 22
BE - Belgio 20
NL - Olanda 19
TW - Taiwan 19
BD - Bangladesh 16
ES - Italia 16
ID - Indonesia 14
AT - Austria 12
EC - Ecuador 11
PK - Pakistan 11
ZA - Sudafrica 11
IL - Israele 10
IQ - Iraq 10
LT - Lituania 9
CO - Colombia 8
IR - Iran 8
EU - Europa 7
AE - Emirati Arabi Uniti 6
CL - Cile 6
PY - Paraguay 6
AU - Australia 5
BA - Bosnia-Erzegovina 5
MY - Malesia 5
LB - Libano 4
MA - Marocco 4
SA - Arabia Saudita 4
CH - Svizzera 3
ET - Etiopia 3
KE - Kenya 3
NO - Norvegia 3
NZ - Nuova Zelanda 3
TT - Trinidad e Tobago 3
UG - Uganda 3
VE - Venezuela 3
AZ - Azerbaigian 2
DK - Danimarca 2
DZ - Algeria 2
EE - Estonia 2
JO - Giordania 2
MK - Macedonia 2
NI - Nicaragua 2
RO - Romania 2
TN - Tunisia 2
UY - Uruguay 2
AO - Angola 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BY - Bielorussia 1
CR - Costa Rica 1
EG - Egitto 1
GA - Gabon 1
GD - Grenada 1
GR - Grecia 1
GT - Guatemala 1
HN - Honduras 1
JM - Giamaica 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LI - Liechtenstein 1
LU - Lussemburgo 1
MN - Mongolia 1
NP - Nepal 1
PE - Perù 1
PH - Filippine 1
RS - Serbia 1
SC - Seychelles 1
SN - Senegal 1
SV - El Salvador 1
TH - Thailandia 1
UZ - Uzbekistan 1
Totale 10.959
Salva come PNG Salva come JPEG
Città #
Singapore 934
Chandler 653
Jacksonville 610
Dublin 471
Southend 264
Beijing 253
Ashburn 251
Princeton 231
Dallas 194
Izmir 188
Nanjing 186
Los Angeles 132
Santa Clara 120
Cambridge 101
Dearborn 101
The Dalles 90
Wilmington 90
Tongling 82
New York 79
Altamura 71
Boardman 70
Ann Arbor 67
Munich 63
Chieti 60
Nanchang 57
Pescara 49
Shenyang 49
Buffalo 47
Ho Chi Minh City 40
São Paulo 32
Warsaw 30
Tianjin 29
Hangzhou 26
Hebei 26
Rome 26
Seoul 26
Woodbridge 26
Milan 25
Redondo Beach 24
Kunming 23
Chennai 21
Grevenbroich 21
Washington 21
Hanoi 20
Hong Kong 20
Stockholm 20
Brooklyn 19
Augusta 18
Atlanta 17
Boston 17
Denver 17
Tokyo 17
Brussels 16
Toronto 16
Jiaxing 15
Poplar 15
Helsinki 14
Jinan 14
London 14
Norwalk 14
San Mateo 14
Taichung 14
Brno 13
Houston 13
Mexico City 13
Ningbo 13
Chicago 12
Collecorvino 12
Montreal 12
Rio de Janeiro 12
Belo Horizonte 11
Orange 11
Phoenix 11
Turku 11
Nuremberg 10
Changsha 9
Council Bluffs 9
Hefei 9
Dong Ket 8
Latina 8
Montesilvano 8
New Delhi 8
Orem 8
Vienna 8
Auburn Hills 7
Frankfurt am Main 7
Hyderabad 7
Johannesburg 7
Olomouc 7
Ancona 6
Biên Hòa 6
Falls Church 6
Guangzhou 6
Lanzhou 6
San Francisco 6
Seattle 6
Tappahannock 6
Varallo 6
Amsterdam 5
Brasília 5
Totale 6.598
Salva come PNG Salva come JPEG
Nome #
Assessing EGFR mutations. 217
ALK protein analysis by IHC staining after recent regulatory changes: A comparison of two widely used approaches, revision of the literature, and a new testing algorithm 179
A unique microRNA signature associated with plaque instability in humans. 172
ALK rearrangement testing by FISH analysis in non-small-cell lung cancer patients: Results of the first italian external quality assurance scheme 158
Validation of a new algorithm for a quick and easy RT-PCR-based ALK test in a large series of lung adenocarcinomas: Comparison with FISH, immunohistochemistry and next generation sequencing assays 156
Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: Toward a real-time liquid biopsy for treatment 149
Effective assessment of egfr mutation status in bronchoalveolar lavage and pleural fluids by next-generation sequencing. 149
Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors 134
EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. 133
Plasma exosome microRNA profiling unravels a new potential modulator of adiponectin pathway in diabetes: effect of glycemic control 133
A unique microRNA signature associated with ischemic stroke in humans 132
Down regulation of high in normal-1 (HIN-1) is a frequent event in stage I non-small cell lung cancer and correlates with poor clinical outcome. 126
Association between prostaglandin E receptor subtype EP4 overexpression and unstable phenotype in atherosclerotic plaques in human. 125
ROS1 Gene Fusion in Advanced Lung Cancer in Women: A Systematic Analysis, Review of the Literature, and Diagnostic Algorithm 124
AKT1(E17K) in human solid tumours 122
Why anti-PD1/PDL1 therapy is so effective? Another piece in the puzzle 122
ATP-binding cassette transporter A1 (ABCA1) overexpression in hypercholesterolemic plaques: a potential molecular explanation 121
ABCA-1 expression is reduced in atherosclerotic plaques from hypertensive patients: a new potential link between hypertension and atherosclerosis 118
Optimizing Single Agent Panitumumab Therapy in Pre-Treated Advanced Colorectal Cancer 117
Extraordinary and prolonged erlotinib-induced clinical response in a patient with EGFR wild-type squamous lung cancer in third-line therapy: A case report 116
Mutational profile of GNAQQ209 in human tumors. 115
Reduction of atherothrombotic burden before stent deployment in non-ST elevation acute coronary syndromes: Reduction of myocardial necrosis achieved with nose-dive manual thrombus aspiration (REMNANT) trial. A volumetric intravascular ultrasound study 115
Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features. 114
Int6 expression can predict survival in early-stage non-small cell lung cancer patients. 114
Dramatic response to crizotinib in ROS1 fluorescent in situ hybridization- and immunohistochemistry-positive lung adenocarcinoma: a case series. 113
Alterations of P16 (MTS1) in node-positive non-small cell lung carcinomas. 113
Human telomerase reverse transcriptase mRNA expression assessed by real-time reverse transcription polymerase chain reaction predicts chemosensitivity in patients with ovarian carcinoma. 111
Overexpression of ABCA1 in human plaques exposed to hypercholesterolemia: the role of microRNA modulation 111
Identification of an aberrantly spliced form of HDMX in human tumors: a new mechanism for HDM2 stabilization. 110
Prediction of survival in stage I lung carcinoma patients by telomerase function evaluation 107
Quantification of EGFR Mutations in Plasma of NSCLC Patients: An Early Predictor of Clinical Response to Tyrosine Kinase Inhibitor 107
Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. 106
Survival prediction of stage I lung adenocarcinomas by expression of 10 genes. 106
Correspondence - In Reply - Limitations of Single-Strand Conformation Polymorphism Analysis As a High-Throughput Method for the Detection of EGFR Mutations in the Clinical Setting 105
Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives 105
Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. 104
Prognostic value of p21(WAF1) and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up 103
PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma. 103
Hypertension is a determinant of ABCA1 expression in atherosclerotic plaques from hypercholesterolemic patients 103
Association between cigarette smoking and FHIT gene alterations in lung cancer. 103
Absence of somatic mutations in the coding region of the waf1/cip1 gene in human breast, lung and ovarian carcinomas - a polymorphism at codon-31. 103
POLE exonuclease domain mutations in endometrial carcinoma: a case report 102
The chromosomal location of the mouse mammary tumor gene Int6 and related pseudogenes in the mouse genome. 101
IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. 101
Early prediction of resistance to tyrosine kinase inhibitors by plasma monitoring of EGFR mutations in NSCLC: A new algorithm for patient selection and personalized treatment 101
Telomerase activity as a prognostic indicator in Stage I Non- Small Cell Lung Cancer -Gruppo Italiano di Patologia Molecolare II Riunione Scientifica. Pisa 20-22 Giugno99 100
Lung tumours from non-smoking subjects: A p53-related genetic instability in a subset of cases. 100
p53 alterations in non-small cell lung cancer correlate with metastatic involvement of hilar and mediastinal lymph nodes 100
Survivin gene expression in early-stage non-small cell lung cancer. 100
Complex Mutations & Subpopulations of Deletions at Exon 19 of EGFR in NSCLC Revealed by Next Generation Sequencing: Potential Clinical Implications. 100
Frequent mutations in the neurotrophic tyrosine receptor kinase gene family in large cell neuroendocrine carcinoma of the lung. 99
microRNAs Derived from Circulating Exosomes as Noninvasive Biomarkers for Screening and Diagnosing Lung Cancer. 99
Enriched SSCP: a highly sensitive method for the detection of unknown mutations. Application to the molecular diagnosis of lung cancer in sputum samples. 98
The Integrated Oncology Program of the Italian Ministry of Health. Analytical and clinical validation of new biomarkers for early diagnosis: network, resources, methodology, quality control, and data analysis. 98
Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors. 98
Gene mutations in small-cell lung cancer (SCLC): Results of a panel of 6 genes in a cohort of Italian patients 98
Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. 97
Early prediction of response to tyrosine kinase inhibitors by quantification of EGFR mutations in plasma of NSCLC patients 97
Host genetic background effect on the frequency of mouse mammary tumor virus-induced rearrangements of the int-1 and int-2 loci in mouse mammary tumors. 96
mdm2 gene alterations and mdm2 protein expression in breast carcinomas 94
Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: An update from clinical practice 94
EGFR molecular profiling in advanced NSCLC: a prospective phase II study in molecularly/clinically selected patients pretreated with chemotherapy. 93
The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies 93
Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. 93
mRNA markers of breast cancer nodal metastases: comparison between mammaglobin and carcinoembryonic antigen in 248 patients. 92
The chromosome location of the human homolog of the mouse mammary tumor-associated gene INT6 and its status in human breast carcinomas. 92
Bronchioloalveolar carcinoma: K-ras mutations are constant events in the mucinous subtype 91
Prostatic cancer: molecular bases. 91
Adjuvant osimertinib treatment in patients with early stage NSCLC (IB-IIIA): pathological pathway adaptations 90
Genetic analysis of lung tumors of non-smoking subject: p53 gene mutations are constantly associated with loss of heterozygosity at the FHIT locus 89
Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones. 89
Hypertension modulates miR-145 expression in human atherosclerotic plaques 89
Int-6, a highly conserved, widely expressed gene, is mutated by mouse mammary tumor virus in mammary preneoplasia. 88
Detection of gene mutations on cytological specimens: clinical implications 88
An innovative diagnostic strategy for the detection of rare molecular targets to select cancer patients for tumor-agnostic treatments 88
PI3KCA mutation status is of limited prognostic relevance in ER-positive breast cancer patients treated with hormone therapy 86
BRAF as a positive predictive biomarker: Focus on lung cancer and melanoma patients 85
Clinical significance of cyclin D1 expression in patients with node-positive breast carcinoma treated with adjuvant therapy. 84
MDM4 (MDMX) localizes at the mitochondria and facilitates the p53-mediated intrinsic-apoptotic pathway. 84
Assessment of the prognostic relevance of serum anti-p53 antibodies in epithelial ovarian cancer. 84
Nucleotide and deduced amino acid sequences of tumor gene INT6. 82
Predictive markers in lung cancer: A few hints for the practicing pathologist 82
Serum anti-p53 antibodies in the follow-up of patients with advanced ovarian carcinoma. 81
Telomerase Activity as a Prognostic Indicator in Stage I Non-Small Cell Lung Cancer 79
Real-world data on NGS diagnostics: A survey from the Italian Society of Pathology (SIAPeC) NGS Network 78
Evaluation of FHIT gene alterations in ovarian cancer 77
p53 mutations and histologic type of invasive breast carcinoma. A polymerase chain reaction-single-strand conformation polymorphism and immunohistochemical analysis. 76
p21 RNA and protein expression in non-small cell lung carcinomas: evidence of p53-independent expression and association with tumoral differentiation. 75
Stabilita’ del dna in campioni citologici conservati in fase liquida 75
Expression of 90K (Mac-2 BP) correlates with distant metastasis and predicts survival in stage I non-small cell lung cancer patients 73
Reduced expression of INT-6/eIF3-p48 in human tumors. 73
Multiple regions of chromosome 6q affected by loss of heterozygosity in primary human breast carcinomas. 72
p53 mutations and histological type of invasive breast carcinoma. 72
Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. 72
P53 and C-erbb-2 alterations in in-situ and invasive ductal breast carcinomas - a genetic and immunohistochemical analysis. 71
p21WAF1 immunohistochemical expression in breast carcinoma: correlations with clinicopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alterations and relapse-free survival. 70
Cell cycle-related gene abnormalities and product expression in esophageal carcinoma. 69
Preoperative serum antibodies against the p53 protein in patients with ovarian and endometrial cancer. 69
Cyclin-D1-gene amplification and expression in breast carcinoma: relation with clinicopathologic characteristics and with retinoblastoma gene product, p53 and p21WAF1 immunohistochemical expression. 68
Identification of microRNAs 758 and 33b as potential modulators ofABCA1 expression in human atherosclerotic plaques 67
Totale 10.217
Salva come PNG Salva come JPEG
Categoria #
all - tutte 45.046
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 45.046
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021364 0 0 0 0 0 132 17 3 77 93 6 36
2021/2022603 18 7 8 131 31 23 13 38 50 33 84 167
2022/20231.709 144 216 70 212 193 345 96 105 233 12 46 37
2023/2024762 68 24 44 23 50 229 153 33 4 27 2 105
2024/20252.249 114 451 376 49 56 74 81 88 235 103 246 376
2025/20262.070 351 245 376 563 478 57 0 0 0 0 0 0
Totale 11.197